Date: 2015-03-26
Type of information: Services contract
Compound: inhibitors of multiple ion channel targets
Company: Asahi Kasei Pharma (Japan) Evotec (Germany)
Therapeutic area: undisclosed
Type agreement: services contract
Action mechanism:
Disease: undisclosed
Details: * On March 26, 2015, Evotec announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Under the terms of the agreement, Evotec will use its world-class ion channel platform to identify inhibitors of multiple ion channel targets.
Financial terms: Financial terms were not disclosed.
Latest news:
